• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071).
  

PubMed=9850071
Keshelava N., Seeger R.C., Groshen S., Reynolds C.P.
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Cancer Res. 58:5396-5405(1998)

PubMed=11212268
Thompson P.M., Maris J.M., Hogarty M.D., Seeger R.C., Reynolds C.P., Brodeur G.M., White P.S.
Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.
Cancer Res. 61:679-686(2001)

PubMed=11507071
Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C., Gomer C.J., Triche T.J., Reynolds C.P.
Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Cancer Res. 61:6185-6193(2001)

PubMed=16822308; DOI=10.1186/1471-2407-6-177; PMCID=PMC1533846
Dam V., Morgan B.T., Mazanek P., Hogarty M.D.
Mutations in PIK3CA are infrequent in neuroblastoma.
BMC Cancer 6:177.1-177.10(2006)

PubMed=18724359; DOI=10.1038/nature07261; PMCID=PMC2672043
Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A., Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P., Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A., Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M., Maris J.M.
Identification of ALK as a major familial neuroblastoma predisposition gene.
Nature 455:930-935(2008)

PubMed=23202128; DOI=10.1038/ng.2493; PMCID=PMC3557959
Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y., Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N., Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma.
Nat. Genet. 45:12-17(2013)

PubMed=24792489; DOI=10.1007/s11060-014-1456-8
Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P., Lau L.M.S.
Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations.
J. Neurooncol. 119:17-26(2014)